BioNTech SE (BNTX) Income from Non-Controlling Interests (2018 - 2019)
BioNTech SE (BNTX) reported Income from Non-Controlling Interests of $17710.2 for Q4 2019, down 87.26% on a YoY basis from $138973.0 in Q4 2018, and down 87.26% sequentially from $138973.0 in Q4 2018.
BioNTech SE (BNTX) Income from Non-Controlling Interests (2018 - 2019) Analysis & Trends
BioNTech SE (BNTX) has 2 years of Income from Non-Controlling Interests data on file, last reported at $17710.2 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | BioNTech SE | 21.56 Bn | 21.56 Bn | 668.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 17,710.20 |
| Dec 31, 2018 | 138,973.00 |
| Sep 30, 2018 | -54,667.07 |